Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Breast Cancer

  Free Subscription


Articles published in J Natl Cancer Inst

Retrieve available abstracts of 85 articles:
HTML format



Single Articles


    January 2022
  1. MOSKOWITZ CS
    Towards Using Breast Cancer Risk Prediction Models for Guiding Screening Decisions.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506526. doi: 10.1093.
    PubMed    


  2. KERLIKOWSKE K, Chen S, Golmakani MK, Sprague BL, et al
    Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population.
    J Natl Cancer Inst. 2022 Jan 13. pii: 6506541. doi: 10.1093.
    PubMed     Abstract available


    December 2021
  3. SCHLEE VILLODRE E, Hu X, Eckhardt BL, Larson R, et al
    NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis.
    J Natl Cancer Inst. 2021 Dec 10. pii: 6459176. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  4. BORGES VF
    The Expanded Role of Ovarian Suppression for Young Women's Breast Cancer: An Era of Patient-Tailored Decision Making.
    J Natl Cancer Inst. 2021 Nov 25. pii: 6440063. doi: 10.1093.
    PubMed    


  5. LAMBERTINI M, Boni L, Michelotti A, Magnolfi E, et al
    Long-Term Outcomes with Pharmacological Ovarian Suppression during Chemotherapy in Premenopausal Early Breast Cancer Patients.
    J Natl Cancer Inst. 2021 Nov 25. pii: 6440062. doi: 10.1093.
    PubMed     Abstract available


  6. NEGOITA S, Ramirez-Pena E
    Prevention of Late Recurrence: An Increasingly Important Target for Breast Cancer Research and Control.
    J Natl Cancer Inst. 2021 Nov 8. pii: 6423213. doi: 10.1093.
    PubMed    


  7. PEDERSEN RN, Esen BO, Mellemkjaer L, Christiansen P, et al
    The Incidence of Breast Cancer Recurrence 10-32 Years after Primary Diagnosis.
    J Natl Cancer Inst. 2021 Nov 8. pii: 6423212. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  8. LYNN BCD, Chernyavskiy P, Gierach GL, Rosenberg PS, et al
    Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region.
    J Natl Cancer Inst. 2021 Sep 11. pii: 6368686. doi: 10.1093.
    PubMed     Abstract available


  9. SPRAGUE BL, Lowry KP, Miglioretti DL, Alsheik N, et al
    Changes in Mammography Use by Women's Characteristics During the First 5 Months of the COVID-19 Pandemic.
    J Natl Cancer Inst. 2021;113:1161-1167.
    PubMed     Abstract available


    August 2021
  10. KLAR N, Adams S
    RE: Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
    J Natl Cancer Inst. 2021 Aug 16. pii: 6352668. doi: 10.1093.
    PubMed    


  11. KURIAN AW, Abrahamse P, Bondarenko I, Hamilton AS, et al
    Association of Genetic Testing Results with Mortality Among Women with Breast Cancer or Ovarian Cancer.
    J Natl Cancer Inst. 2021 Aug 9. pii: 6346986. doi: 10.1093.
    PubMed     Abstract available


    July 2021
  12. YEH JM, Lowry KP, Schechter CB, Diller LR, et al
    Breast Cancer Screening Among Childhood Cancer Survivors Treated Without Chest Radiation: Clinical Benefits and Cost-Effectiveness.
    J Natl Cancer Inst. 2021 Jul 29. pii: 6330765. doi: 10.1093.
    PubMed     Abstract available


  13. WHITE J
    Benefit vs Harm of Internal Mammary Node Irradiation for Node-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329830. doi: 10.1093.
    PubMed    


  14. POORTMANS PM, Struikmans H, De Brouwer P, Weltens C, et al
    Side-ffects 15 Years after Lymph Node Irradiation in Breast Cancer: Randomized EORTC Trial 22922/10925.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329829. doi: 10.1093.
    PubMed     Abstract available


  15. PAN IW, Oeffinger KC, Shih YT
    Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening.
    J Natl Cancer Inst. 2021 Jul 28. pii: 6329641. doi: 10.1093.
    PubMed     Abstract available


  16. BADVE SS, Penault-Llorca F, Reis-Filho JS, Deurloo R, et al
    Determining PD-L1 Status in Patients with Triple-Negative Breast Cancer: Lessons Learned from IMpassion130.
    J Natl Cancer Inst. 2021 Jul 20. pii: 6324819. doi: 10.1093.
    PubMed     Abstract available


  17. ALAGOZ O, Lowry KP, Kurian AW, Mandelblatt JS, et al
    Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling.
    J Natl Cancer Inst. 2021 Jul 14. pii: 6319940. doi: 10.1093.
    PubMed     Abstract available


  18. SEMBA T, Wang X, Xie X, Cohen EN, et al
    Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment.
    J Natl Cancer Inst. 2021 Jul 12. pii: 6313157. doi: 10.1093.
    PubMed     Abstract available


    June 2021
  19. VINAYAK S, Davidson NE
    Selection of Adjuvant Endocrine Therapy for Women with Breast Cancer in Menopausal Transition: Is It Simpler than We Thought?
    J Natl Cancer Inst. 2021 Jun 8. pii: 6292091. doi: 10.1093.
    PubMed    


  20. DACKUS GM, Jozwiak K, Sonke GS, van der Wall E, et al
    Adjuvant Aromatase Inhibitors or Tamoxifen following Chemotherapy for Perimenopausal Breast Cancer Patients.
    J Natl Cancer Inst. 2021 Jun 8. pii: 6292098. doi: 10.1093.
    PubMed     Abstract available


  21. RUGO HS, Loi S, Adams S, Schmid P, et al
    PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2021 Jun 7. pii: 6294407. doi: 10.1093.
    PubMed     Abstract available


    May 2021
  22. WAGNER LI, Tooze JA, Hall DL, Levine BJ, et al
    Targeted eHealth Intervention to Reduce Breast Cancer Survivors' Fear of Recurrence: Results from the FoRtitude Randomized Trial.
    J Natl Cancer Inst. 2021 May 31. pii: 6290009. doi: 10.1093.
    PubMed     Abstract available


  23. CUI W, Francis PA, Loi S, Hickey M, et al
    Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.
    J Natl Cancer Inst. 2021 May 28. pii: 6287661. doi: 10.1093.
    PubMed     Abstract available


  24. KANTOR O, King TA, Shak S, Russell CA, et al
    Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 May 19. pii: 6278359. doi: 10.1093.
    PubMed     Abstract available


  25. ZHANG J, Yang M
    RE: Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
    J Natl Cancer Inst. 2021 May 18. pii: 6277733. doi: 10.1093.
    PubMed    


    April 2021
  26. HERSCH J, Barratt A, McGeechan K, Jansen J, et al
    Informing Women About Overdetection in Breast Cancer Screening: Two-year Outcomes from a Randomized Trial.
    J Natl Cancer Inst. 2021 Apr 19. pii: 6237906. doi: 10.1093.
    PubMed     Abstract available


  27. VAN DEN BROEK JJ, Schechter CB, van Ravesteyn NT, Janssens ACJW, et al
    Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History.
    J Natl Cancer Inst. 2021;113:434-442.
    PubMed     Abstract available


  28. MAGUIRE S, Perraki E, Tomczyk K, Jones ME, et al
    Common Susceptibility Loci for Male Breast Cancer.
    J Natl Cancer Inst. 2021;113:453-461.
    PubMed     Abstract available


  29. MAGBANUA MJM, Hendrix LH, Hyslop T, Barry WT, et al
    Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
    J Natl Cancer Inst. 2021;113:443-452.
    PubMed     Abstract available


  30. FRANZOI MA, Eiger D, Ameye L, Ponde N, et al
    Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
    J Natl Cancer Inst. 2021;113:462-470.
    PubMed     Abstract available


  31. FEIGELSON HS, Bodelon C, Powers JD, Curtis RE, et al
    Body Mass Index and Risk of Second Cancer among Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210655. doi: 10.1093.
    PubMed     Abstract available


  32. DEKKER J, Stege CAM, Versteeg KS
    Re: Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2021 Apr 5. pii: 6210765. doi: 10.1093.
    PubMed    


  33. RICHMAN IB, Long JB, Hoag JR, Upneja A, et al
    Comparative Effectiveness of Digital Breast Tomosynthesis for Breast Cancer Screening among Women 40-64 Years Old.
    J Natl Cancer Inst. 2021 Apr 3. pii: 6209735. doi: 10.1093.
    PubMed     Abstract available


  34. YU KD, Ge JY, Liu XY, Mo M, et al
    Cyclophosphamide-free Adjuvant Chemotherapy for Ovarian Protection in Young Women with Breast Cancer: a Randomized Phase 3 Trial.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209077. doi: 10.1093.
    PubMed     Abstract available


  35. LAMBERTINI M, Partridge AH
    Cyclophosphamide-free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women with Breast Cancer.
    J Natl Cancer Inst. 2021 Apr 2. pii: 6209078. doi: 10.1093.
    PubMed    


    March 2021
  36. POLLEY MC
    On the Quest of Risk Stratification in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206391. doi: 10.1093.
    PubMed    


  37. CHIC N, Luen SJ, Nuciforo P, Salgado R, et al
    Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.
    J Natl Cancer Inst. 2021 Mar 31. pii: 6206389. doi: 10.1093.
    PubMed     Abstract available


  38. PISANO ED, Gatsonis C, Sparano J, Troester MA, et al
    RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2021 Mar 30. pii: 6203812. doi: 10.1093.
    PubMed    


  39. REINER AS, Watt GP, John EM, Lynch CF, et al
    Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women.
    J Natl Cancer Inst. 2021 Mar 29. pii: 6199433. doi: 10.1093.
    PubMed     Abstract available


  40. DU Z, Gao G, Adedokun B, Ahearn T, et al
    Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.
    J Natl Cancer Inst. 2021 Mar 26. pii: 6189099. doi: 10.1093.
    PubMed     Abstract available


  41. HOULAHAN KE
    Do Breast Cancer Risk Scores Work for You?
    J Natl Cancer Inst. 2021 Mar 25. pii: 6189097. doi: 10.1093.
    PubMed    


  42. O'LEARY B, Cutts RJ, Huang X, Hrebien S, et al
    Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
    J Natl Cancer Inst. 2021;113:309-317.
    PubMed     Abstract available


  43. KAPOOR PM, Mavaddat N, Choudhury PP, Wilcox AN, et al
    Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk.
    J Natl Cancer Inst. 2021;113:329-337.
    PubMed     Abstract available


    February 2021
  44. LOHMANN AE, Soldera SV, Pimentel I, Ribnikar D, et al
    Association of Obesity with Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis.
    J Natl Cancer Inst. 2021 Feb 23. pii: 6147022. doi: 10.1093.
    PubMed     Abstract available


  45. EMENS LA, Molinero L, Loi S, Rugo HS, et al
    Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study.
    J Natl Cancer Inst. 2021 Feb 1. pii: 6125365. doi: 10.1093.
    PubMed     Abstract available


  46. LIM B
    PD-L1 in Breast Cancer: The oad to the erfect iomarker is raught with ncertainty.
    J Natl Cancer Inst. 2021 Feb 1. pii: 6125363. doi: 10.1093.
    PubMed    


  47. BLAES A, Konety S, Zordoky B
    Response to Schoormans.
    J Natl Cancer Inst. 2021;113:214-215.
    PubMed    


  48. PIMENTEL I, Chen BE, Lohmann AE, Ennis M, et al
    The Effect of Metformin vs Placebo on Sex Hormones in Canadian Cancer Trials Group MA.32.
    J Natl Cancer Inst. 2021;113:192-198.
    PubMed     Abstract available


    January 2021
  49. VAN RAVESTEYN NT, Schechter CB, Hampton JM, Alagoz O, et al
    Trade-Offs Between Harms and Benefits of Different Breast Cancer Screening Intervals Among Low-Risk Women.
    J Natl Cancer Inst. 2021 Jan 30. pii: 6124199. doi: 10.1093.
    PubMed     Abstract available


  50. PACE LE, Keating NL
    Should Women at Lower-Than-Average Risk of Breast Cancer Undergo Less Frequent Screening?
    J Natl Cancer Inst. 2021 Jan 30. pii: 6124198. doi: 10.1093.
    PubMed    


  51. TRAPANI D, Yves Douillard J, Winer EP, Burstein H, et al
    The global landscape of treatment standards for breast cancer.
    J Natl Cancer Inst. 2021 Jan 27. pii: 6120790. doi: 10.1093.
    PubMed     Abstract available


  52. MANDELBLATT JS, Zhou X, Small BJ, Ahn J, et al
    Deficit Accumulation Frailty Trajectories of Older Breast Cancer Survivors and Non-Cancer Controls: The Thinking and Living with Cancer Study.
    J Natl Cancer Inst. 2021 Jan 23. pii: 6117333. doi: 10.1093.
    PubMed     Abstract available


  53. FARBER R, Houssami N, Wortley S, Jacklyn G, et al
    Impact of Full-Field Digital Mammography Versus Film-Screen Mammography in Population Screening: A Meta-Analysis.
    J Natl Cancer Inst. 2021;113:16-26.
    PubMed     Abstract available


  54. BRAWLEY OW, Paller CJ
    Overdiagnosis in the Age of Digital Cancer Screening.
    J Natl Cancer Inst. 2021;113:1-2.
    PubMed    


    December 2020
  55. ALABOUSI M, Wadera A, Kashif Al-Ghita M, Al-Ghetaa RK, et al
    Performance of Digital Breast Tomosynthesis, Synthetic Mammography and Digital Mammography in Breast Cancer Screening: A Systematic Review and Meta-Analysis.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054799. doi: 10.1093.
    PubMed     Abstract available


  56. BORDE J, Ernst C, Wappenschmidt B, Niederacher D, et al
    Performance of breast cancer polygenic risk scores in 760 female CHEK2 germline mutation carriers.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054801. doi: 10.1093.
    PubMed     Abstract available


  57. ELMORE JG, Lee CI
    Keeping Pace with Technology Advances in Breast Cancer Screening: Synthetic 2D Images Outperform Digital Mammography.
    J Natl Cancer Inst. 2020 Dec 29. pii: 6054798. doi: 10.1093.
    PubMed    


  58. REIS-FILHO JS, Davidson NE
    Ki67 Assessment in Breast Cancer: Are We There yet?
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053793. doi: 10.1093.
    PubMed    


  59. NIELSEN TO, Leung SCY, Rimm DL, Dodson A, et al
    Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053794. doi: 10.1093.
    PubMed     Abstract available


  60. RAKOVITCH E, Sutradhar R, Nofech-Mozes S, Gu S, et al
    21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma in Situ.
    J Natl Cancer Inst. 2020 Dec 28. pii: 6053792. doi: 10.1093.
    PubMed     Abstract available


  61. HOUGHTON SC, Eliassen H, Tamimi RM, Willett WC, et al
    Central adiposity and subsequent risk of breast cancer by menopause status.
    J Natl Cancer Inst. 2020 Dec 26. pii: 6050830. doi: 10.1093.
    PubMed     Abstract available


  62. CHECK DK, Winn AN, Fergestrom N, Reeder-Hayes KE, et al
    Response to Strassels and Durham.
    J Natl Cancer Inst. 2020;112:1280.
    PubMed    


  63. BLAES AH, Dang C
    Trastuzumab: Weighing the Benefits and the Risks.
    J Natl Cancer Inst. 2020;112:1181-1182.
    PubMed    


  64. MACINNIS RJ, Knight JA, Chung WK, Milne RL, et al
    Comparing Five-Year and Lifetime Risks of Breast Cancer in the Prospective Family Study Cohort.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029579. doi: 10.1093.
    PubMed     Abstract available


  65. ETZIONI R, Shen Y, Shih YT
    Identifying Preferred Breast Cancer Risk Predictors: A Holistic Perspective.
    J Natl Cancer Inst. 2020 Dec 10. pii: 6029577. doi: 10.1093.
    PubMed    


    November 2020
  66. KERLIKOWSKE K, Bissell MCS, Sprague BL, Buist DSM, et al
    Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium.
    J Natl Cancer Inst. 2020 Nov 10. pii: 5970482. doi: 10.1093.
    PubMed     Abstract available


  67. MA D, Chen SY, Ren JX, Pei YC, et al
    Molecular features and functional implications of germline variants in triple-negative breast cancer.
    J Natl Cancer Inst. 2020 Nov 5. pii: 5956725. doi: 10.1093.
    PubMed     Abstract available


  68. YADAV S, LaDuca H, Polley EC, Hu C, et al
    Racial and ethnic differences in multigene hereditary cancer panel test results for women with breast cancer.
    J Natl Cancer Inst. 2020 Nov 4. pii: 5955835. doi: 10.1093.
    PubMed     Abstract available


  69. COLDITZ GA, Toriola AT
    Refining the focus on early life and adolescent pathways to prevent breast cancer.
    J Natl Cancer Inst. 2020 Nov 2. pii: 5951178. doi: 10.1093.
    PubMed    


  70. HOFVIND S, Sebuodegard S, Botteri E
    Response to Zahl.
    J Natl Cancer Inst. 2020;112:1175.
    PubMed    


    October 2020
  71. SCHOORMANS D
    RE: Cardiovascular disease in breast cancer survivors: an important topic in breast cancer survivorship.
    J Natl Cancer Inst. 2020 Oct 15. pii: 5924374. doi: 10.1093.
    PubMed    


    September 2020
  72. DIGNAM JJ
    Disparities in Breast Cancer: Narrowing the Gap.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912531. doi: 10.1093.
    PubMed    


  73. ZAHL PH
    RE: Breast cancer mortality after implementation of organized population-based screening in Norway.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912532. doi: 10.1093.
    PubMed    


  74. ALBAIN KS, Gray RJ, Makower DF, Faghih A, et al
    Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer in the randomized TAILORx trial.
    J Natl Cancer Inst. 2020 Sep 28. pii: 5912534. doi: 10.1093.
    PubMed     Abstract available


  75. STRASSELS SA, Durham DD
    Re: Concurrent Opioid and Benzodiazepine Prescriptions Among Older Women Diagnosed With Breast Cancer.
    J Natl Cancer Inst. 2020 Sep 21. pii: 5909658. doi: 10.1093.
    PubMed    



  76. Correction: Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank.
    J Natl Cancer Inst. 2020 Sep 15. pii: 5906112. doi: 10.1093.
    PubMed    


  77. HELZLSOUER KJ, Reedy J
    Data Sharing for the Public Good.
    J Natl Cancer Inst. 2020;112:867-868.
    PubMed    


    August 2020
  78. ROBERTS AW, Eiffert S, Wulff-Burchfield EM, Dusetzina SB, et al
    Opioid use disorder and overdose in older adults with breast, colorectal, or prostate cancer.
    J Natl Cancer Inst. 2020 Aug 17. pii: 5893484. doi: 10.1093.
    PubMed     Abstract available


  79. ANURAG M, Ellis MJ
    Response to Jezequel, Patsouris, Guette, et al.
    J Natl Cancer Inst. 2020;112:865.
    PubMed    


    July 2020
  80. FLORIS G, Richard F, Hamy AS, Jongen L, et al
    Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    J Natl Cancer Inst. 2020 Jul 6. pii: 5867914. doi: 10.1093.
    PubMed     Abstract available


  81. LOHMANN AE, Goodwin PJ
    Obesity and Breast Cancer: Expanding the Hypothesis Space.
    J Natl Cancer Inst. 2020 Jul 6. pii: 5867915. doi: 10.1093.
    PubMed    


  82. BENEFIELD HC, Allott EH, Reeder-Hayes KE, Perou CM, et al
    Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
    J Natl Cancer Inst. 2020;112:728-736.
    PubMed     Abstract available


    May 2020
  83. LIN CH, Yap YS, Lee KH, Yeo W, et al
    Response to Sung, Rosenberg, and Yang.
    J Natl Cancer Inst. 2020;112:547-548.
    PubMed    


    April 2020
  84. CHIARELLI AM, Blackmore KM, Mirea L, Done SJ, et al
    Annual vs Biennial Screening: Diagnostic Accuracy Among Concurrent Cohorts Within the Ontario Breast Screening Program.
    J Natl Cancer Inst. 2020;112:400-409.
    PubMed     Abstract available


    July 2019
  85. BARLOW WE, Beaber EF, Geller BM, Kamineni A, et al
    Evaluating screening participation, follow-up and outcomes for breast, cervical and colorectal cancer in the PROSPR consortium.
    J Natl Cancer Inst. 2019 Jul 11. pii: 5530599. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: